1. Introduction {#sec1}
===============

Bone regeneration is one of the main challenges facing us in the daily clinic. Immediately after a tooth extraction, normal biological processes remodel the alveolar bone limiting in some cases the possibility of future implant placement. Different strategies for the preservation of that bone have been explored in recent years. Other conditions, such as trauma, tumor resective surgery, or congenital deformities, require even higher technical and biological requirements to generate the necessary bony structure for the occlusal rehabilitation of the patient. To overcome these anatomical limitations in terms of bone volume, different approaches have been proposed to either improve the implant osteointegration or to augment the bone anatomy where it will be placed \[[@B1], [@B2]\]. Autogenous bone graft is still considered the "gold standard" due to its osteogenic, osteoconductive, and osteoconductive properties \[[@B3], [@B4]\]. However, it also presents several limitations including the need for a second surgery, limited availability, and morbidity in the donor area \[[@B5]\]. Therefore, other biomaterials such as allogeneic grafts, with osteoconductivity and osteoinductive capacities \[[@B6], [@B7]\], and xenogeneic grafts \[[@B8], [@B9]\] and alloplastic biomaterials \[[@B10]\], with osseoconductive potential, were proposed. All these materials, although acceptable, are not suitable in many conditions and usually require additional consideration in the decision process \[[@B11]\]. Additionally, the bone quantity and quality that can be obtained with these materials are often limited.

The use of bioactive molecules, alone or in combination with the previously described materials, has, therefore, become a major area of interest thanks to their high potential. When using this kind of procedures, it is important to consider (1) the delivery method and (2) the molecule itself. Bioactive molecules can be transported into the defect area as a solution or a gel, embedded in sponges, adhered to solid scaffolds and, more recently, included in particles of different sizes. Using these methods, PDGF (platelet-derived growth factor), FGF (fibroblast growth factor), IGF (insulin growth factor), Runx2, Osterix (Osx), LIM domain mineralization protein (LMP), BMP (bone morphogenic protein) and, more recently, periostin have been proposed as potential candidates for regeneration procedures within the oral cavity, including bone and periodontal tissues \[[@B12], [@B13]\]. These molecules have been tested alone or in combination with stem cells \[[@B14]\] using several*in vitro* and*in vivo* strategies \[[@B15]\].

Consequently, within the context of this review, we intend to review the delivery methods of bioactive molecules with the purpose of bone regeneration, with a particular focus on polymeric nano/microparticles, especially those with PLGA as main component, to encapsulate the growth factor BMP-2. An overview of the biological functions of bone morphogenetic proteins and an analysis of the different parameters affecting the physicochemical properties of these systems are presented. Synthesis method, particle size and morphology, use of stabilizers and their incidence in the colloidal stability, protective function, and surface functionality will be discussed. In addition, we explore the different strategies that can be used to optimize the encapsulation efficiency and release kinetics, main parameters that determine the correct development of polymeric carriers used in tissue-engineered bone processes.

2. BMPs: Action and Regulation {#sec2}
==============================

For bone regeneration, in particular, bone morphogenetic growth factors (BMP) are probably the more tested group of molecules. Since 1965, when Urist \[[@B16]\] showed that the extracted bone BMPs could induce bone and cartilage formation when implanted in animal tissue, an increasing number of reports have tested its*in vivo* application and biological foundation when used in bone defects \[[@B17]--[@B19]\]. BMPs are members of the TGF-*β* superfamily of proteins \[[@B20]\]. The BMP family of proteins groups more than 20 homodimeric or heterodimeric morphogenetic proteins, which functions in many cell types and tissues, not all of them being osteogenic \[[@B21]\]. BMPs can be divided into 4 subfamilies based on their function and sequence, being BMP-2, BMP-4, and BMP-7 the ones with osteogenic potential \[[@B21]\]. The actions of BMPs include chondrogenesis, osteogenesis, angiogenesis, and extracellular matrix synthesis \[[@B22]\]. Within this family of proteins, BMP-2 has been the most studied. It has osteoinductive properties that promote the formation of new bone by initiating, stimulating, and amplifying the cascade of bone formation through chemotaxis and stimulation of proliferation and differentiation of the osteoblastic cell lineage \[[@B5], [@B17], [@B19], [@B20]\]. The absence of it, as studied in knockout models, leads to spontaneous fractures that do not heal with time \[[@B23]\]. In fact, other models have demonstrated that the absence of either BMP-4 \[[@B24]\] or BMP-7 \[[@B25]\] do not lead to bone formation and function impairment which demonstrate the compensatory effect produced by BMP-2 alone \[[@B26]\].

Many cell types in bone tissue produce BMPs, including osteoprogenitor cells, osteoblasts, chrondrocytes, platelets, and endothelial cells. This secreted BMP is then stored in the extracellular matrix where it mostly interacts with collagen type IV \[[@B27]\]. During the repair and remodeling processes, osteoclast resorptive activity induces the release of BMPs to the medium so that they are suspended and can interact with nearby cells to initiate the subsequent osteogenic process \[[@B28]\].

A BMP in the extracellular matrix binds to cell surface receptors BMPR-I and BMPR-II and activates the Smad cytoplasmic proteins or the MAPK pathway \[[@B29]\]. When BMPR-I is activated, BMPR-II is recruited and activated as well \[[@B30]\]. The activation of the complexes BMPR-I and BMPR-II leads to the activation of several Smads (1, 5, and 8) that also activate Smad 4 and they all form protein complexes that are transported into the nucleus where Runx2, Dlx5, and Osterix genes (important in osteogenesis) are activated \[[@B26], [@B27]\] ([Figure 1](#fig1){ref-type="fig"}). Similarly, when the MAPK pathway is activated, it leads to induction of Runx2 transcription and, therefore, to bone differentiation \[[@B31]\]. A number of extracellular and intracellular antagonists have also been described, including noggin, chordin, and gremlin or Smads 6, 7, and 8b, respectively \[[@B32]\].

2.1. Clinical Use of BMP-2 {#sec2.1}
--------------------------

Today, the BMP-2 is commercially available under different brand names and concentrations. It usually consists of a collagen absorbable sponge embedded with recombinant human BMP-2. In 2002, it was approved by the FDA as an alternative of autogenous bone grafting in anterior lumbar interbody fusion \[[@B33]\]. Later, in 2007, the FDA approved the use of rhBMP-2 as an alternative for autogenous bone grafting in the increase of the alveolar crest defects associated with the tooth extraction maxillary sinus pneumatization \[[@B33]\].

Beside the applications in spine clinical studies, where very high concentrations are used (AMPLIFY, rhBMP-2, 40 mg), clinical studies have supported its use in the oral cavity. BMPs have been used in periodontal regeneration, bone healing, implant osteointegration, oral surgery with orthodontic purposes, bone pathology sequel repair, distraction osteogenesis, and endodontic reparative surgery \[[@B28], [@B34]\]. However, it has shown more promising results in cases where only bone tissue is to be regenerated, including preimplant site development, sinus lift, vertical and horizontal ridge augmentation, and dental implant wound healing \[[@B35]\]. In this sense, it has been shown that the use of rhBMP-2 induced the formation of bone suitable for placement of dental implants and their osteointegration \[[@B36]\]. Furthermore, it appears that the newly formed bone has similar properties to the native bone and is, therefore, capable of supporting denture occlusal forces \[[@B37]\]. In the particular case of sinus lifting, where bone deficiency is greater and, therefore, supportive therapies can be more helpful, a recent meta-analysis found a total of 3 human studies and 4 animal trials ([Table 1](#tab1){ref-type="table"}) \[[@B38]\]. In summary, the included studies concluded that rhBMP-2 induces new bone formation with comparable bone quality and quantity of newly formed bone to that induced by autogenous bone graft. In some cases, even higher bone quality and quantity have been reported \[[@B39]\].

Conversely, recent studies report severe complications after its use \[[@B40]\]. Even more, high doses have also associated with carcinogenic effects, which led the authors to emphasize the need for better guidelines in BMP clinical use \[[@B41]\]. Not so drastic, recent studies are highlighting the negative side effects and risks of its application, making high emphasis on potential bias of nonreproducible industry sponsored research, especially when used in spinal fusion \[[@B43], [@B42], [@B44]\]. The use of rhBMP-2 has been shown to increase the risks for wound complications and dysphagia with high effectiveness and harms misrepresentation through selective reporting, duplicate publication, and underreporting \[[@B43]\]. Specifically in oral bone regenerative applications, a report in sinus lift concluded that the use of BMP-2 promotes negative effects on bone formation when combined with anorganic bovine bone matrix versus anorganic bovine bone alone \[[@B45]\], in contrast with previous reports and reviews \[[@B38]\]. Taking together this information, it can be concluded that it is of extreme importance to be careful with the clinical use of new products, avoiding off-label applications. It is also important to highlight the need for more and better clinical research.

To overcome these limitations, new strategies, such as the use of*ex vivo* BMP-2-engineered autologous MSCs \[[@B46]\], encapsulation of the protein in different biomaterials, or delivery by gene therapy, are being explored in recent years.

The development of these technologies is based on some biological facts.*In vitro* effects of BMPs are observed at very low dosages (5--20 ng/mL), although current commercially available rhBMPs are used in large dosages (up to 40 mg of some products) \[[@B28]\]. This is probably due to an intense proteolytic consumption during the early postsurgical phases. It is important to know the proper sequence of biological events that lead to normal tissue healing. Then, this knowledge can be used to intervene at the specific time frame where our therapy is intended to act \[[@B15]\]. Effective bone formation, as described above, is a sequential process. Therefore, the inductive agent should be delivered at a maintained concentration during a timeframe. In this sense, as in many other processes in medicine, it has been recently demonstrated that long-term release of BMP-2 is more effective than short-term over a range of doses \[[@B47]\]. It is also important to note that the role of other molecular pathways and crosstalk between the different components playing in bone regeneration is not perfectly understood yet, and, therefore, more research has to be conducted.

What is known so far, in summary, is that BMPs, specifically BMP-2, is of utility for promoting bone regeneration \[[@B28]\]. However, the currently FDA-approved BMP-2 delivery system (INFUSE, Medtronic Sofamor Danek, Inc.) presents important limitations \[[@B48]\]. Firstly, protein is quickly inactivated. Therefore, its biological action disappears, maybe even before the blood clot that forms after the surgery is being organized. Second, the recombinant protein is delivered in an absorbable collagen sponge. Thus, the distribution of the BMP in a liquid suspension embedded into a collagen sponge makes it impossible to be certain that the protein is reaching the ideal target. Therefore, where, when, and for how long a dose of BMP-2 is reached (determined by the delivery method) are important factors. Because of that, new forms of BMP-2 delivery are being developed. These new technologies have to guarantee a higher half-life of the protein and a stepped release, to increase the effects on the desired cell targets. The biotechnology opens the door to be able to provide a solution to these limitations.

Biodegradable nanoparticles (nanospheres and nanocapsules) have developed as a promising important tool for the delivery of macromolecules via parenteral, mucous, and topical applications \[[@B49]--[@B52]\]. Well-established biodegradable polymers such as poly(acid D, L-lactic) or poly(D, L-lactic-co-glycolic) have been widely used in the preparation of nanoparticles in recent decades because of its biocompatibility and full biodegradability \[[@B53]\]. However, it is known that certain macromolecules, such as proteins or peptides, may lose activity during their encapsulation, storage, delivery, and release \[[@B54]\]. To overcome this problem, the addition of stabilizers such as oxide polyethylene (PEO) or the coencapsulation with other macromolecules and its derivatives seem to be a promising strategy.

3. Polymeric Colloidal Particles to Encapsulate Hydrophilic Molecules {#sec3}
=====================================================================

Generally, polymeric colloidal particles are hard systems with a homogeneous spherical shape composed by natural or synthetic polymers. In order to encapsulate hydrophilic molecules as proteins or nucleic acids, it is necessary to optimize the polymeric composition and the synthesis method. In this process, a high encapsulation efficiency, maintenance of the biological activity of the encapsulated biomolecule, and obtaining of an adequate release pattern have to be achieved \[[@B55]--[@B57]\]. Several delivery systems of BMP2 (and other growth factors, GFs) using polymeric particles have been described in the literature. Most of them are microparticulated systems using the biocompatible and biodegradable PLGA copolymer as main component \[[@B58], [@B59]\]. Taking into account the incorporation of BMP2 to the carrier system, encapsulation is preferred to absorption because the growth factors are more protected against environmental factors in the medium and may have better control over the delivery and release to achieve the desired concentrations in specific site and time \[[@B60]\].

Normally, if the GFs are related with bone regeneration processes, nano-microparticles are trapped in a second system as hydrogels or tissue engineering scaffolds, which also play an important role in the release profile of GFs from these particles \[[@B60]\]. The nano-microparticles have allowed the development of multiscale scaffold, thereby facilitating control of the internal architecture and adequate patterns of mechanical gradients of cells and signaling factors \[[@B61]\].

All steps, from the synthesis method and its characteristics, the encapsulation process, or the final surface modification for a targeted delivery, determine the characteristics of these systems and their main goal: the controlled release of bioactive GFs.

3.1. Synthesis Methods {#sec3.1}
----------------------

It is possible to found several procedures to encapsulate hydrophilic molecules as proteins or nucleic acids in polymeric nano/microparticles. Phase separation \[[@B62]\] or spray drying \[[@B63]\] techniques have been reported to encapsulate hydrophilic molecules. However, in the case of proteins, the most normally used procedure to encapsulate them into PLGA micro- and nanoparticles is the double-emulsion (water/oil/water, W/O/W) solvent evaporation technique \[[@B57], [@B64]\]. A schematic description of this technique is presented in [Figure 2](#fig2){ref-type="fig"}. In a general way, PLGA is dissolved in an organic solvent and emulsified, using mechanical agitation or sonication, with water containing an appropriate amount of protein. Thus, a primary water/oil (W/O) emulsion is obtained. In the second phase, this emulsion is poured into a large polar phase leading to an immediate precipitation of the particles as a consequence of the polymer shrinkage around droplets of the primary emulsion. This phase may be composed of a water solution of a stabilizer (surfactant) or ethanol-water mixtures \[[@B65], [@B66]\]. After stirring, the organic solvent is rapidly extracted by evaporation under vacuum. A wide list of different modifications have been tested in this procedure in order to obtain a micro/nanocarrier system with adequate colloidal stability, high encapsulation efficiency, adequate bioactivity, and, finally, a long-time release profile with low "initial burst." The goal is to avoid a high amount of protein (\>60%) being released very quickly (24 hours), which is one of the biggest problems of a controlled release system \[[@B58]\].

3.2. Organic Solvent {#sec3.2}
--------------------

Hans and Lowman show different examples of organic solvents used in multiple emulsion processes. Normally, dichloromethane (DMC), ethyl acetate, acetone and their mixtures can be used \[[@B64]\]. In the first step, a good organic solvent with low water solubility to facilitate the emulsification process and low boiling point for an easy evaporation would be the election. However, the structure of the encapsulated protein molecules can be affected and denaturation processes and loss of biological activity appear when they interact with a typical organic solvent as DMC \[[@B55]\]. Ethyl acetate, on the other hand, exerts less denaturating effects with a lower incidence on the bioactivity of the encapsulated proteins \[[@B67]\].

Other important factors related with the organic solvent are their physical properties that affect how the polymer tails self-organize in the shell of the emulsion droplets and modify the nanoparticle morphology and the encapsulation efficiency \[[@B68]\]. In this way, a higher water solubility of the organic solvent, that is, ethyl acetate, favors a rapid solvent removal. Additionally, the solvent removal rate can be controlled by adjusting the volume of the polar phase as well as the shear stress during the second emulsification step. An increase of these two parameters increases the diffusion rate of ethyl acetate from primary microparticles to outer aqueous phase, resulting in their rapid solidification \[[@B69]\]. It also enhances the encapsulation efficiency and minimizes the contact-time between protein molecules and organic solvent \[[@B70]\], obtaining at the same time a lower burst effect and a slower drug release from the microparticles \[[@B69]\].

3.3. Particle Size and Morphology {#sec3.3}
---------------------------------

Particle size is an important parameter and one of the main goals of the delivery polymeric system. Microspheres, from a few micrometers up to 100 *μ*m, are suitable for oral delivery, mucosal adhesion, or inside scaffold use, that is, for bone regeneration. Nanoscale dimension of the carrier offers enhanced versatility when compared with particles of larger size. This is due to the fact that they have higher colloidal stability, improved dispersibility and bioavailability, more reactive surface and also, can deliver proteins or drugs inside and outside of the corresponding cells \[[@B71]\]. BMP2 promotes bone formation and induces the expression of other BMPs and initiates the signaling pathway from the cell surface by binding to two different surface receptors \[[@B22]\]. Therefore, the BMP2 carrier particles must release it into the extracellular medium. Since cellular intake of PLGA nanoparticles is very fast, the intaking process can be limited by an increase in size from nano- to microparticles \[[@B72]\]. However, the interaction between particles and cells is strongly influenced by particle size. If cell internalization is desired, the particle must be comprised in the submicron scale at an interval between 2 and 500 nm \[[@B73]\]. Moreover, this size is needed for a rapid distribution after parenteral administration in order to reach different tissues through different biological barriers. In addition, the intake by macrophages is minimized with a diameter of nanoparticles under 200 nm and even smaller \[[@B64], [@B74]\]. As discussed by Yang et al. \[[@B75]\], slight modifications of the synthesis procedure can suppose drastic effects on the size or particle morphology and, therefore, in the protein encapsulation efficiency and kinetic release.

In double emulsion processes, the first emulsification step largely determines the particle size while the second emulsification step, characterized by the solvent elimination and polymer precipitation, mainly affects the particle morphology \[[@B68]\]. However, the use of surfactant solutions as the polar medium of the second emulsification process and the volume ratio between organic and polar phases in this step has shown an important influence in the final size \[[@B76]\]. Therefore, the correct election of the organic solvent, the polymer concentration, the addition of surfactant, and the emulsification energy allow controlling the size of the system.

The incorporation of poloxamers (F68) in the organic solvent of the primary emulsification helps to increase the colloidal stability of the first dispersion by being placed at the water/oil interface. This reduces the particle size in comparison with pure PLGA nanoparticles in which the only stability source comes from electric charge of the carboxyl groups of the PLGA \[[@B77]\]. It is normal to obtain spherical micro/nanospheres with a polymeric porous core. A typical SEM micrograph of PLGA nanoparticles obtained by W/O/W emulsion using a mixture of organic solvents (DCM/acetone) and ethanol/water as second polar medium is shown in [Figure 3](#fig3){ref-type="fig"}, in which the spherical shape and uniform size distribution are the main characteristics. The outer polymeric shell in the second emulsification step pushed the water droplets to the inner core according to their solidification process \[[@B78]\]. This process allows producing particles like capsules with a core-shell structure in which the inner core has a low polymer density. [Figure 4](#fig4){ref-type="fig"} shows a typical core-shell structure in which the polymer precipitates and shrinks around the water droplets during the solvent change of the second phase and the subsequent organic solvent evaporation process \[[@B79]\]. In this case, the process of solidification of the polymer is influenced and determined by the miscibility of the organic solvent with the second polar phase and the removal rate.

The polymeric shell often presents channels or pores as a consequence of the inner water extrusion due to osmotic forces. This can reduce the encapsulation efficiency and favors a fast initial leakage with the unwanted "burst release" \[[@B75]\]. This modification of internal structure of the particles is usually indicated assigning the term "nanosphere" to the system with a core consisting of a homogeneous polymer matrix. The bioactive agent is dispersed within them, while the core-shell structure would be similar to a "nanocapsule" where the biomolecule is preferably in the aqueous cavity surrounded by the polymeric shell \[[@B60]\] (see [Figure 2](#fig2){ref-type="fig"}).

3.4. Stabilizer Agents {#sec3.4}
----------------------

### 3.4.1. Colloidal Stability {#sec3.4.1}

The double emulsion method normally requires the presence of stabilizers in order to confer colloidal stability during the first emulsification step, to prevent the coalescence of the emulsion droplets, and, later, to maintain the stability of the final nano/microparticles \[[@B80]\]. Polyvinyl alcohol (PVA) and PEO derivate as poloxamers (also named pluronics) have been used in most cases \[[@B65], [@B76]\]. Others include natural surfactants, such as phospholipids \[[@B81], [@B82]\]. In some cases, it is possible to avoid surfactants if the particles have an electrostatic stability contribution, that is, from the uncapped end carboxyl groups of the PLGA molecules \[[@B83]\].

As it has been previously commented, PVA and poloxamers have shown their efficiency in synthetizing both nano- and microparticles, affecting not only the stability of the systems but also their size and morphology. Thus, a size reduction effect has been found using PVA in the external water phase, affecting at the same time the surface porosity, mainly in microsized particles \[[@B76]\]. A comparative study between this and phospholipids (di-palmitoyl phosphatydilcholine, DPPC) as stabilizers showed that DPPC could be a better emulsifier than PVA to produce nano- and microparticles. With this method, a much lower amount of stabilizer was needed to obtain a similar size. In the same study, a higher porosity on the particle surface for the PVA emulsified nanospheres was shown \[[@B81]\].

On the other hand, the combination of PLGA with poloxamers has shown positive effects for the nano- and microsystems in terms of stability \[[@B84]\]. The use of these surfactants in the first or second steps of the W/O/W emulsion procedure leads to different situations. Thus, if poloxamers are blended with PLGA in the organic phase of the primary emulsification, an alteration of the surface roughness is obtained. However, if these are added in the inner water phase, an increase of porosity is found \[[@B65]\]. In addition, their inclusion in the polar phase of the second emulsification step also generates hydrophilic roughness surfaces. A quantification of this is shown in [Figure 5](#fig5){ref-type="fig"}, in which the electrophoretic mobility of both PLGA pure and PLGA/pluronic F68 nanoparticles is measured as a function of the pH of the medium. The observed dependence with this parameter is a consequence of the weak acid character of the PLGA carboxyl groups. When poloxamer molecules are present at the interface, a systematic reduction of mobility was found as a consequence of the increase in the surface roughness. The hydrophilic surfactant chains spread out towards the solvent originating a displacement of the shear plane and the consequent mobility reduction \[[@B77], [@B83]\].

The final PLGA particle size is primarily controlled by electrostatic forces and is not significantly affected by the presence or nature of poloxamer stabilizers \[[@B83]\]. The recognition of the nanocarriers by the mononuclear phagocytic system (MPS) can be significantly altered if the surface of colloidal particles is modified by using PEO block copolymer of the poloxamer molecules. The steric barrier given by these surfactant molecules prevents or minimizes the adsorption of plasma protein and decreases the recognition by macrophages \[[@B85]\]. The size of microspheres is also unaffected by the coencapsulation of poloxamers. The system containing poloxamer-PLGA blends drive to an inner structure displaying small holes and cavities in relation with microspheres of pure PLGA with a compact matrix-type structure \[[@B65]\].

Microparticles formulated by poloxamer in the second polar medium have completely different surface than the PVA ones, almost without pores \[[@B76]\]. A comparison between different poloxamers shows that the hydrophilic-lipophylic balance (HBL) of the surfactant plays a crucial role determining the surfactant-polymer interactions and controlling the porosity and roughness of the nano-microparticles \[[@B65], [@B86]\].

In a similar manner to surfactants, polymer characteristics, like the hydrophobicity grade, the molecular weight or the hydrolysis degradation rate, can strongly influence the particle morphology. Therefore, the polymer composition of the particles greatly affects its structure and properties. This is why it is usual to use other polymers in order to modify the behavior and application of the particles. In this way, polyethylene glycol (PEG) of different chain length is frequently used to modify the surface characteristics. With PEG, particles are more hydrophilic and with rougher surfaces which affects the MPS action by increasing the circulating-time and half-life*in vivo*, like the presence of PEO chains \[[@B87]\]. Additionally, PEG chains also provide colloidal stability via steric stabilization. Pegylated-PLGA nano- or microparticles can be normally obtained by using in the synthesis method PLGA/PEG di- and triblock copolymers \[[@B88], [@B89], [@B57]\]. Natural polymers as chitosan, besides modifying the hydrophobicity-hydrophilicity ratio of the surface, also confer them a mucoadhesive character \[[@B90]\].

### 3.4.2. Encapsulation Efficiency and Bioactivity {#sec3.4.2}

Furthermore, the use of stabilizers (surfactants or polymers) also influences the encapsulation efficiency and the protein stability. In fact, for the W/O/W solvent evaporation process, the chlorinated organic solvent used for the first emulsification could degrade protein molecules encapsulated in this step if they come into contact with the organic/water interface, causing their aggregation or denaturation \[[@B91]\]. The polymer-protein interaction, the shear stress for the emulsification process, and the pH reduction derived from PLGA polymer degradation can also produce the same situation with the subsequent loss of biological activity of the encapsulated biomolecules. Different strategies to prevent it have been used. For example, an increase of the viscosity around protein molecules can help to isolate them from their microenvironment \[[@B92]\]. In this way, viscous products, such as starch, have been used to prevent protein instability \[[@B93]\]. These authors coencapsulate BMP2 with albumin inside starch microparticles using other biodegradable polymer, poly-*ε*-caprolactone, instead of PLGA. The BMP2 retained its bioactivity. Despite a low encapsulation rate, beside an initial burst followed by an uncompleted release, the amount of BMP2 needed at the beginning was lower \[[@B93]\]. The combination of PEO surfactants with PLGA (blended in the organic phase) can also preserve the bioactivity of microencapsulated proteins \[[@B94]\] or nucleic acids \[[@B66]\].

However, in most cases, the coencapsulation of GFs with other biomolecules was the preferred strategy. Thereby, serum albumins (SA) have shown the capacity to limit the aggregation-destabilization of several proteins incited by the water/organic solvent interface of the primary emulsification process \[[@B95], [@B96]\]. White et al. encapsulated lysozyme inside PLGA-PEG microparticles. In addition to the protective function, they also observed an important increase of the entrapment efficiency when human SA was coencapsulated with lysozyme and BMP2 \[[@B89]\]. d\'Angelo et al. used heparin as stabilizer because it forms a specific complex with several GFs, stabilizes their tridimensional structure, and promotes their bioactivity. An encapsulation efficiency of 35% was increased to 87% using bovine SA as a second stabilizer to encapsulate two natural proangiogenic growth factors inside PLGA-poloxamer blended nanoparticles. The*in vitro* cellular assays showed the preservation of the biological activity of GFs up to one month \[[@B97]\].

The use of more hydrophilic surfactants (poloxamers) or polymers (PEG) in the inner water phase or blended with PLGA in the organic phase of the primary emulsion reduces the interaction of encapsulated proteins with the hydrophobic PLGA matrix. This prevents disrupting the structure of the protein molecules and helps, at the same time, to neutralize the acidity generated by the hydrolytic degradation of the PLGA \[[@B98]\]. In some cases, the combination of several stabilizers, such as poloxamers, trehalose, and sodium bicarbonate, has been shown to preserve the integrity of encapsulated proteins but it also reduces the encapsulation efficiency \[[@B99]\].

As a general rule, encapsulation efficiency increases with the size of the particles \[[@B64]\]. Additionally, the adequate stabilization of the primary emulsion by amphiphilic polymers and a rapid solidification (precipitation) of polymer in the second step are favorable parameters for enhancing protein entrapment efficiency in the W/O/W emulsion technique \[[@B69]\].

The tendency of BMP2 to interact with hydrophobic surfaces may decrease the loss of encapsulated protein during the extraction of the solvent phase. This favors a higher entrapment but it lowers the later extraction \[[@B88]\]. An optimal protein encapsulation is obtained when pH of the internal and external water phases is near the isoelectric point of the protein \[[@B74]\]. Blanco and Alonso \[[@B65]\] observed a reduction in the protein encapsulation efficiency when poloxamer was coencapsulated in the primary emulsion. This highlights the main role played by the protein-polymer interaction in the encapsulation efficiency and the later release process. However, too much emulsifier may also result in a reduction of the encapsulation efficiency \[[@B81]\]. Therefore, an equilibrium between the emulsification powder of the surfactant and their concentration is needed.

3.5. Release Profile {#sec3.5}
--------------------

The release profile represents one of the most important characteristics of a nano/micro particulate carrier system since their development has a main final objective: the adequate release of the encapsulated bioactive molecules to reach the desired clinical action.

The release pattern of protein encapsulated in PLGA micro/nanoparticles can present different behavior. It is possible to find a continuous release when the diffusion of the biomolecule is faster than the particle erosion. This process involves a continuous diffusion of the protein from the polymer matrix before the PLGA particle is degraded in lactic and glycolic acid monomers by hydrolysis \[[@B56]\]. A biphasic release characterized by an initial burst at or near the particle surface followed by a second phase in which protein is progressively released by diffusion has also been described. The second phase can be enhanced by bulk erosion of PLGA shell and matrix which results in an important increase of pores and channels \[[@B57]\]. A third triphasic release profile has been found when a lag release period occurs after initial burst and until polymer degradation starts \[[@B100]\]. Finally, it is possible to obtain an incomplete protein release as a consequence of additional factors related with the protein-polymer interaction or protein instability. [Figure 6](#fig6){ref-type="fig"} illustrates the different release profiles previously described. The optimal carrier system should be capable of releasing a controlled concentration gradient of growth factors in the appropriate time, preventing or at least reducing or controlling the initial burst effect \[[@B101]\]. A controlled initial burst followed by a sustained release significantly improves the*in vivo* bone regeneration \[[@B102]--[@B104]\].

Giteau et al. \[[@B92]\] present an interesting revision on "How to achieve a sustained and complete release from PLGA microparticles." They begin by analyzing the influence of the release medium and sampling method on the release profile and highlight the significance of the centrifugation cleaning process or the release medium volume. Adjusting to adequate values the centrifugation speed or the buffer volume, it is possible to separate micro/nanoparticles from protein-containing release medium in a very easy way. This allows for stable and reproducible release patterns. On the other hand, to ensure a better protein release profile, modification of the microparticle formulation and microencapsulation process in order to preserve protein aggregation has to be performed. Protein stability has to be maintained by preventing the formation of harmful medium. For example, the synthesis formulation can be modified to use more hydrophilic polymers, since they have been shown to reduce the initial burst and to deliver bioactive proteins over long time periods.

The most relevant strategies are referenced below. Drug release from PLGA nano/microparticles can be controlled by the polymer molecular weight and the relation between monomers (lactide/glycolide) so that an increase in glycolic acid accelerates the weight loss of polymer due to the higher hydrophilicity of the matrix \[[@B57]\]. A mixture of different PLGA nanoparticles obtained using 50 : 50 and 75 : 50 latide/glycolide ratio has shown a great potential for protein drug delivery with a higher initial burst from PLGA 50 : 50. A slow release period has been observed for PLGA 75 : 50 encapsulating a glycoprotein (*α*-1-antitrypsin) with clinic activity in some pulmonary diseases \[[@B105]\].

On the other hand, a faster erosion of the microspheres with reduction in the PLGA molecular weight due to the facility of water penetration and the subsequent polymer degradation has been described \[[@B65]\]. Schrier et al. working with microspheres prepared by w/o/w using different types of PLGA analyzed the important role of the molecular weight, lactide-glycolide relation, and acid residues \[[@B106]\]. The amount of rhBMP2 adsorbed on the microparticle surface increased with the hydrophobicity of the polymer. At the same time, the release was in correlation with the degradation profile of the different polymers \[[@B106]\].

Thus, the use of more hydrophilic polymers reduces the hydrophobic protein-polymer interaction. This effect favors a more homogeneous distribution in the polymer matrix and increases the water uptake in the microspheres. Thus, the release rate of rhBMP2 encapsulated in microspheres composed by a PEG-PLGA di-block copolymer is increased with the PEG content of the polymer matrix \[[@B88]\]. A similar result was obtained using PLGA-PEG-PLGA triblock copolymers \[[@B89]\]. In this case, modifying the monomer relation (lactide-glycolide) in the PLGA and increasing the amount of PLGA-PEG-PLGA in the formulations, the release profile of BMP-2 coencapsulated with human SA in microespheres was adjustable. Similarly, the interaction of lysozyme with poloxamer 188 before their encapsulation produces a sustained release over 3 weeks without any burst effect. In the same line, using PLGA-PEG-PLGA as polymer, a sustained release of bioactive lysozime was extended over 45 days when the protein was complexed with poloxamer 188 previously to the encapsulation \[[@B107]\]. However, the presence of PEG300 as an additive of the inner phase of microparticles during the encapsulation process also influences the protein distribution and the release profile. In this case there is a decrease of the initial burst but with less overall release \[[@B88]\].

On the other hand, the use of PLGA-poloxamers blends is useful to obtain a sustained release for more than one month without any incidence in the high initial burst \[[@B97], [@B74]\]. However, for an encapsulated plasmid inside nanoparticles obtained by PLGA-poloxamer blends, the hydrophobicity of the surfactant allows prolonging the release up to 2 weeks in a controlled manner. Moreover, a complete release was reached for the PLGA-poloxamer blend instead PLGA nanoparticles, in which the maximum release was around 40% \[[@B66]\].

PLGA and poloxamers (pluronic F68) blends can also be used to obtain nanocomposite vesicles by a double emulsion process. These vesicles are suitable for the encapsulation of hydrophobic and hydrophilic molecules. The presence of pluronic affects the colloidal stability of the vesicles and the release pattern of the encapsulated molecules. These vesicles present a wall of 30 nm and the drug is encapsulated in the presence of the poloxamer \[[@B108]\].

Other strategies include the use of different compounds to increase the release time. Thus, BMP2 encapsulated in PLGA-PVA nanoparticles (around 300 nm) showed higher encapsulation efficiency and a short-time release profile with a very high initial burst. However, with the same synthesis procedure (w/o/w) but using PHBV (Poly(3 hydroxybutyrateco-3-hydroxivalerate)), BMP7 loaded nanocapsules had less encapsulation efficiency despite a long-time delivery. Nevertheless, the maximum released amount was lower. This difference in the release profile was due to the difference in hydrophilicity and degradation rates of both polymers \[[@B109]\]. Similarly, PLGA-poloxamer blend nanoparticles were superficially modified by introducing chitosan in the second step of the synthesis. This method showed a sustained release profile for up to 14 days without any initial important burst. In this case, a recombinant hepatitis B antigen was used \[[@B90]\]. Moreover, the use of heparin conjugated with PLGA porous microspheres has also been described to obtain a long-time delivery system reducing at the same time the initial burst. In these systems, heparin was immobilized onto the nano/microparticle surface. The release was controlled by using the binding affinities of heparin to several growth factors including BMP2. In this case, the initial burst was reduced to 4--7% during first day followed by a sustained release of about 1% per day \[[@B47]--[@B111]\].

The initial burst release may be attenuated by the fabrication of double-wall microspheres, that is, core-shell microparticles. The presence of a PLA shell reduces the release rate of BSA encapsulated in the PLGA core and extends the duration of the release profile up to two months. Moreover, an increase in the PLA molecular weight influences the rate of particle erosion, which further slows the protein release \[[@B112]\].

The modification of the viscosity in the environment of microparticles additionally influences the release pattern. Viscosity can control the burst at earliest time point and promote a sustained release. This situation has been shown for rhBMP2-PLGA microspheres embedded in a chitosan-thioglycolic acid hydrogel (Poloxamer 407) \[[@B113]\]. Yilgor et al. also incorporated the nanoparticles of their sequential delivery system into a scaffold composed by chitosan and chitosan-PEO \[[@B114]\]. In other work, PLGA/PVA microspheres with encapsulated BMP2 were combined with different composite biomaterials (gelatin hydrogel or polypropylene fumarate). The sustained release of the bioactive molecule was extended over a period of 42 days.*In vivo* results indicate the importance of the composite characteristics. In this case, an enhanced bone formation was obtained when the PLGA microparticles were incorporated into the more hydrophobic matrix (polypropylene fumarate) \[[@B115], [@B116]\].

Finally, [Table 2](#tab2){ref-type="table"} summarizes important information about different parameters related to the use of PLGA based nano- or microparticles to encapsulate, transport, and release growth factors (mainly BMP2).

3.6. Gene Therapy for Bone Tissue Engineering: Directed Delivery {#sec3.6}
----------------------------------------------------------------

In the last years, gene therapy has begun to play a role in bone tissue regeneration becoming an alternative method for the delivery of BMP2 \[[@B117], [@B118]\]. Thus, the genes encoding a specific protein can be delivered to a specific cell, rather than the proteins themselves. To reach this purpose, an efficient gene vector is necessary. Viral vectors possess the best transfection efficiency but numerous disadvantages, the most notable of them being the risk of mutagenesis. Nonviral vectors elude these problems but with a significant reduction in the transfection rate \[[@B119]\]. Therefore, intracellular delivery of bioactive agents has become the most used strategy for gene therapy, looking for the adequate transfection and consequent expression of the desired protein \[[@B61]\].

PLGA microspheres obtained by a w/o/w double emulsion process have been used by Qiao et al. to entrap plasmid-BMP2/polyethyleneimine nanoparticles. In this case, a sustained release of these nanoparticles until 35 days without initial burst was found resulting in differentiation of osteoblast promoted by the correct transfection of the delivered biofunctional BMP2-DNA \[[@B120]\].

In spite of the general caution with gene therapy, the genetic delivery of BMP2 has the potentiality of a better safety compared with the delivery of large amounts of recombinant protein \[[@B121]\]. Lu et al. specify the urgent need to develop more efficient delivery nanoparticles and transfection methods in order to apply the nonviral vectors in stem cell engineering and bone regeneration. Although enhanced bone formation has been shown in several recent studies using genes such as HIF-1*α* and miRNAs, new genetic sequences will be discovered and used in bone engineering in the near future that will most likely change our perspective \[[@B122]\].

PLGA nanospheres represent a well-studied biomolecule delivery system that could be applied to cell targeting, in order to enhance the delivery of specific proteins or nucleic acids inside or near the bone engineering reference cells, that is, mesenchymal stem cells \[[@B123]\]. The targeting properties can be supplied by a ligand functionalization strategy: modification of the surface structure of the nanocarrier by conjugating a cell-specific ligand to direct the release of encapsulated biomolecules preferably in close association with the target cells \[[@B124]\]. The use of pegylated nanoparticles with a covalent attachment of different ligands is reported as a potential technique to deliver bone cell-specific biomolecules for bone engineering \[[@B125]\].

Specific antibodies that recognize surface receptors in these cells could be covalently coupled to the surface of PLGA nanoparticles, obtaining "immunonanoparticles." There are several examples of antibody immobilization on surface of PLGA nanoparticles. Kocbek et al. demonstrated the specific recognition of breast tumor cells by a specific monoclonal antibody attached on PLGA fluorescent nanoparticles obtained by W/O/W emulsion process \[[@B126]\]. For the surface covalent attachment, they used a more simple carbodiimide method, which promotes the formation of an amide bond between free carboxylic end groups of PLGA nanoparticles and primary amine groups of the antibody molecule \[[@B63]\]. This procedure can be highly influenced by the presence of stabilizers frequently used to confer colloidal stability to nanoparticles. The electrophoretic mobility of PLGA nanoparticles with an antibody (immuno-*γ*-globuline antihuman C-reactive protein) covalently attached on the surface is shown in [Figure 5](#fig5){ref-type="fig"}. It is necessary to remark the drastic decrease in the mobility values of the antibody-modified nanoparticles with respect to bare PLGA nanoparticles, which could imply low colloidal stability and the subsequent aggregation of the nanosystem. Santander-Ortega et al. proposed a lower antibody loading in which the bare PLGA patches must be coated by a nonionic surfactant in order to obtain immunoreactive stable nanoparticles \[[@B77]\]. Ratzinger et al. indicated that the presence of high poloxamer concentrations decreased the coupling efficiency to carboxylic end groups in PLGA nanoparticles, showing that an equilibrium that combines sufficient stability and the best coupling efficiency is necessary \[[@B80]\]. To prevent this problem, Cheng et al. synthetized carboxyl functionalized PLGA-PEG block copolymer, attaching a specific aptamer to the surface of pegylated nanoparticles via carbodiimide method. In this work, an enhanced drug delivery to prostate tumors has been shown in comparison to equivalent nontargeted nanoparticles \[[@B127]\].

3.7. Scaffolds {#sec3.7}
--------------

The data reported in the literature indicate that PLGA micro/nanoparticles are promising to achieve a sustained, spatial, and temporally controlled delivery of growth factors required for cell growth and cell differentiation. They can be incorporated with cells in solid scaffold or injectable hydrogels \[[@B55]\]. Scaffolds are porous 3D structures normally used to improve tissue-engineered bone \[[@B28]\]. According to Tian et al. \[[@B128]\], a scaffold designed with this objective must have (1) appropriate mechanical strength to support the growth of new bone; (2) appropriate porosity to allow ingrowth of bone-related cells; (3) good biocompatibility allowing the growth of cells on its surface without being rejected by the body; and (4) low toxicity to cells and tissues surrounded and (5) must be able to induce osteogenic differentiation of bone-related stem cells and (6) be biodegradable with nontoxic degradation products that can be eventually replaced by new bone. Additionally, the scaffold for bone regeneration must maintain the delivery or release of BMP (growth factors) "*in situ*" for a long time. In this way, nano/microparticles inside scaffolds are being used to release an adequate flow of these signaling biomolecules and preserve their functional structure \[[@B129]\]. The incorporation of colloidal micro/nanoparticles into fibrous scaffolds adds in the possibility of multiple drugs loading. However, this multidrug system could also involve a decrease of the mechanical properties of the structure and a possible loss of nanoparticles entrapped between the fibers \[[@B130]\]. Considering that the*in vivo* half-life of most biomolecules, especially proteins, is relatively short, it is essential that bioactive scaffolds maintain a desired concentration "*in situ*" to direct tissue regeneration. To do so, an initial release of the encapsulated growth factor in the first hours to quickly get an effective therapeutic concentration followed by a sustained long-time release profile is required \[[@B130]\]. Most of the polymeric particles inserted in scaffold structures are in a micron-scale. The main objective of these microparticles is the protection and temporary control of growth factor delivery. However, given the porosity of these structures, nanoparticles and especially particles of a few microns may become more important since it is possible to design systems with a simple and easy diffusion through the structure. This process could allow the specific recognition of a particular cell type, releasing their encapsulated BMPs in the same environment and helping their differentiation to cell/bone tissue. In any case, the larger-size microspheres might not necessarily be useless for bone regeneration scaffolds. As the microspheres gradually degrade, the space they occupied will be conducive to ingrowth of tissue. In addition to affecting the compression modulus of scaffolds because of their hollow feature, the particle size of microspheres can also influence the release of rhBMP2 \[[@B128]\].

4. Conclusion {#sec4}
=============

The use of polymeric particles using PLGA is a promising system for a spatially and temporally controlled delivery of growth factors that promote cell growth and differentiation in bone engineering and regeneration by means of their incorporation beside cells into solid scaffold or hydrogels.

The PLGA is widely used for its biodegradability and biocompatibility and is approved by FDA and the European Medicines Agency for use in drug delivery systems supplied via parenteral. On the other hand, BMPs are potent growth factors for bone repair and specifically BMP2 shows excellent ability to induce bone formation of adequate quality. The procedure for synthesizing PLGA nano- or microparticles can be modified in their different variables to obtain systems with controlled size, in which it is possible to encapsulate hydrophobic or hydrophilic molecules, with an adequate colloidal stability and the possibility of surface functionalization for targeted delivery.

With this scenario, an optimization of methods and components must balance the structure and morphology of PLGA micro/nanoparticles in order to achieve high encapsulation efficiency of BMP2 and looking for a main goal: control of delivery, reducing the initial burst, and reaching a sustained release profile, preserving the biological activity, and directed to the target cells to minimize the clinical amount needed and allowing a correct bone tissue regeneration.
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![Schematic representation of the main BMP molecular pathway to osteogenesis. BMPs interact with cell surface receptors I and II to activate Smads 1, 5, and 8. These activated Smads activate Smad 4. All together as a protein complex activate Runx2, Dlx5, and Osterix.](BMRI2015-415289.001){#fig1}

![Double emulsion procedure (water/oil/water emulsion, W~1~/O/W~2~) to obtain PLGA micro/nanoparticles. Depending on the synthesis conditions (stabilizers, solvents and mixing procedure) it is possible to obtain micro-nanospheres with a uniform matrix or micro-nanocapsules with a core-shell structure. Immunoparticles used for directed delivery can be obtained by attaching specific antibody molecules on the particle surface.](BMRI2015-415289.002){#fig2}

![Scanning electron microscopy (SEM) photography of PLGA nanoparticles obtained by a double emulsion emulsification procedure. This system with spherical shape, low polydispersity, and nanoscopic scale shows the intended properties for an adequate physiological distribution and cell internalization.](BMRI2015-415289.003){#fig3}

![PLGA/poloxamers188 blend nanoparticles. (a) Scanning transmission electron microscopy (STEM) photography; (b) scanning electron microscopy (SEM) photography. STEM technique allows the analysis of the nanoparticle structure with an internal region with a low polymer density, which is representative of nanocapsules with core-shell structure.](BMRI2015-415289.004){#fig4}

![Electrophoretic mobility versus pH for PLGA nanoparticles with different characteristics. (▼) PLGA, (■) PLGA/poloxamer188 blend, and (∙) PLGA covered by Immuno-*γ*-globulin. The different surface composition affects the electrokinetic behaviour of bare nanoparticles. Surface charge values were screened by the presence of nonionic surfactant as poloxamers, or, in a higher extension, by the presence of antibody molecules attached on the surface.](BMRI2015-415289.005){#fig5}

![Release profiles. (○) BSA release from PLGA nanoparticles with high initial burst release; (red dots line) biphasic model combining a moderate initial burst and a subsequent sustained release; (blue dash line) triphasic model with a lag of release between both initial and sustained release phases; (dash-dot green line) incomplete release.](BMRI2015-415289.006){#fig6}

###### 

Summary of clinical and animal studies using BMP-2 for sinus floor elevation (adapted from \[[@B38]\]). The included studies overall concluded that rhBMP-2 induces new bone formation with comparable bone quality and quantity of newly formed bone to that induced by autogenous bone graft.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                                                                                                  Study design                                                                      Follow-up (months)                                                                          Species (subjects)                                     Core biopsy harvesting (months)   Graft material           \% Newly formed bone   Bone height gain (mm)   Bone width gain (mm)   Bone density (mg/mL)   Immune response   Histology
  ---------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------ --------------------------------- ------------------------ ---------------------- ----------------------- ---------------------- ---------------------- ----------------- --------------------------------------------------------------------------------------------------------------------
  Boyne et al. 2005 \[[@B37]\]                                                                               RCT                                                                               52                                                                                          Human (48)                                             6--11                             0.75 mg/mL rhBMP-2/ACS   NA                     11.29                   Crest: 2.02\           84                     None              NA
                                                                                                                                                                                                                                                                                                                                                                                                                                                            Midpoint: 8.54\                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                            Apical: 11.86                                                   

  1.50 mg/mL rhBMP-2/ACS                                                                                     0.47                                                                              Crest: 1.98\                                                                                134                                                                                                                                                                                                                              
                                                                                                                                                                                               Midpoint: 7.80\                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                               Apical: 10.78                                                                                                                                                                                                                                                                                                                

  Autogenous bone graft; autogenous bone graft + allogeneic bone graft                                       10.16                                                                             Crest: 4.66\                                                                                350                                                                                                                                                                                                                              
                                                                                                                                                                                               Midpoint: 10.17\                                                                                                                                                                                                                                                                                                             
                                                                                                                                                                                               Apical: 10.56                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Triplett et al. 2009 \[[@B131]\]                                                                           RCT                                                                               58                                                                                          Human (160)                                            6                                 1.50 mg/mL rhBMP-2/ACS   NA                     7.83 ± 3.52             NA                     200                    None              Rich vascular marrow space high in cellular content

  Autogenous bone graft (iliac crest, tibia or oral cavity); autogenous bone graft + allogeneic bone graft   9.46 ± 4.11                                                                       283                                                                                         Osteoclasts still present; higher fibrous tissue                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Kao et al. 2012 \[[@B45]\]                                                                                 Prospective                                                                       6--9                                                                                        Human (22)                                             6--9                              rhBMP-2/ACS + ABB        16.04 ± 7.45           NA                      NA                     NA                     None              Fewer ABB particles; less newly formed bone (woven and mature bone structure)

  ABB                                                                                                        24.85 ± 5.82                                                                      More ABB particles remaining; higher newly formed bone (woven and matured bone structure)                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Nevins et al. 1996 \[[@B36]\]                                                                              Prospective                                                                       12                                                                                          Goat (6)                                               12                                rhBMP-2/ACS              NA                     NA                      NA                     NA                     None              Dense isolated trabeculae and bone marrow; osteoblast and osteoclasts; no cortical bone

  ACS/Buffer                                                                                                 Collagenous connective tissue; no evidence of inflammation; no neo-osteogenesis                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Hanisch et al. 1997 \[[@B132]\]                                                                            RCT                                                                               24                                                                                          Nonhuman primate (12)                                  24                                rhBMP-2/ACS              NA                     6.0 ± 0.3               NA                     14.4 ± 2.9             NA                Newly formed bone indistinguishable from residual bone

  ACS                                                                                                        2.6 ± 0.3                                                                         13.9 ± 4.6                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Wada et al. 2001 \[[@B133]\]                                                                               Prospective                                                                       8                                                                                           Rabbit (10)                                            8                                 rhBMP-2/ACS              22.4 ± 4.4             NA                      NA                     NA                     NA                Cortical bone formation in both groups; trabeculae with clear lamellar structure were embedded in fatty marrow

  Autogenous bone graft (iliac crest)                                                                        21.9 ± 4.5                                                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Lee et al. 2013 \[[@B39]\]                                                                                 Prospective                                                                       8                                                                                           Mini-pig (8)                                           8                                 rhBMP-2/ACS              NA                     9.3 ± 0.5               NA                     51.9 ± 3               NA                Newly formed cancellous bone; new bone continuous with resident bone; woven bone in fibrovascular and fatty marrow

  Autogenous bone graft (iliac crest)                                                                        8.6 ± 0.7                                                                         32.9 ± 2.5                                                                                  Irregular and variable bone among different subjects                                                                                                                                                                             
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available; RCT: randomized clinical trial; ACS: absorbable collagen sponge; ABB: anorganic bovine bone.

###### 

Nano/microparticles systems to encapsulate GFs, mainly BMP2 growth factor. Most of them are in the microscopic scale and were used to be entrapped into scaffold of different characteristics. PVA has been the more used surfactant-stabilizer. It is possible to find both, encapsulation and surface adsorption of the growth factors with high-moderate efficiency. The use of heparin as stabilizer reduces significantly the initial burst release, favoring a sustained release in the time. The bioactivity of the GF was preserved in most of the systems and coencapsulation with other biomolecules seems to have a similar effect than the use of surfactants as stabilizers.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Polymers                   Stabilizer                     Size            Encapsulation\         Release                                                                             Biological activity                                                  Reference
                                                                            % EE                                                                                                                                                                            
  -------------------------- ------------------------------ --------------- ---------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------------------- -----------------------------------------
  PLGA                       PVA                            10--20 *µ*m     Adsorbed rhBMP2        20 ng/mL of constant sustained release                                              Better bone formation after 8 weeks                                  Fu et al. 2013 \[[@B43]\]

                                                                                                                                                                                                                                                            

  PLGA                       PVA                            10--100 *μ*m    rhBMP2-BSA\            Burst (20%)\                                                                        BMP2 molecules with bioactivity                                      Tian et al. 2012 \[[@B128]\]
                                                                            69% (BMP)              Sustained until 77% (28 days)                                                                                                                            

                                                                                                                                                                                                                                                            

  PLGA 75 : 25               PVA                            182 *μ*m        82%                    ---                                                                                 Good bone\                                                           Rodríguez-Évora et al. 2014 \[[@B134]\]
                                                                                                                                                                                       defect repair outcomes within 8−12 weeks                             

                                                                                                                                                                                                                                                            

  PLGA                       PVA                            228 *μ*m        60,5%                  30% initial burst. Slower release of 4% per week. After 8 weeks 60% released        No loss of bioactivity                                               Reyes et al. 2013 \[[@B135]\]

                                                                                                                                                                                                                                                            

  PLGA/PEG                   No double emulsion synthesis   100--200 *μ*m   Adsorbed BMP2          13% initial burst. Slower release of 0.01--8% per day. After 23 days 70% released   Substantial bone regeneration of the scaffold                        Rahman et al. 2014 \[[@B136]\]

                                                                                                                                                                                                                                                            

  Different PLGA             PVA                            20--100 *μ*m    30% (uncapped PLGA)\   26--49% (1 day)\                                                                    No loss of bioactivity                                               Lupu-Haber et al. 2013 \[[@B137]\]
                                                                            90% (capped PLGA)      Total after 2 weeks                                                                                                                                      

                                                                                                                                                                                                                                                            

  PLGA 75 : 25               PVA                            5--125 *μ*m     ---                    Initial burst 30% (1 day)\                                                          Higher volumes and surface area coverage of new bone                 Wink et al. 2014 \[[@B138]\]
                                                                                                   Sustained 35 days                                                                                                                                        

                                                                                                                                                                                                                                                            

  PLGA                       Heparin                        200--800 nm     Adsorbed BMP2\         No initial burst. Sustained over 4 weeks                                            Significant reduction of the BMP2 dose for good bone formation       La et al. 2010 \[[@B47]\]
                                                                            94%                                                                                                                                                                             

                                                                                                                                                                                                                                                            

  PLGA                       Heparin- Poloxamer             160 nm          Adsorbed BMP2\         Initial burst (4--7%) linear profile                                                Higher matrix mineralization of regenerated bone                     Chung et al. 2007 \[[@B110]\]
                                                                            100%                                                                                                                                                                            

                                                                                                                                                                                                                                                            

  PLGA                       Heparin                        100--250 nm     Adsorbed 94%           Initial burst 10% (1 day)\                                                          No loss of bioactivity\                                              Jeon et al. 2008 \[[@B111]\]
                                                                                                   60% after 30 days                                                                   Efficacy of administration, amount 50-fold lower                     

                                                                                                                                                                                                                                                            

  PLGA                       PVA                            \~300 nm        80%                    85% initial burst (1 day)                                                           No loss of bioactivity                                               Yilgor et al. 2009 \[[@B114]\]

                                                                                                                                                                                                                                                            

  PLGA (in rings)            PVA                            215 *μ*m        66%                    Moderate burst\                                                                     60% of calvaria defect were healed                                   Rodríguez-Évora et al. 2013 \[[@B139]\]
                                                                                                   Sustained release over 6 weeks                                                                                                                           

                                                                                                                                                                                                                                                            

  PLGA-Poloxamer 188 Blend   Poloxamer                      150 nm          FGF-BSA-Heparin\       40% initial burst (1 day), 60% (30 days)                                            No loss of bioactivity                                               d\'Angelo et al. 2010 \[[@B97]\]
                                                                            60--80%                                                                                                                                                                         

                                                                                                                                                                                                                                                            

  Different PLGA polymers    PVA                            *μ*m order      rhBMP2 adsorption\     20--80% initial burst (1 day)                                                       ---                                                                  Schrier et al. 2001 \[[@B106]\]
                                                                            40--75%                                                                                                                                                                         

                                                                                                                                                                                                                                                            

  PLGA/PEG                   PVA                            37--67 *μ*m     72--99%                33% initial burst (1 day)                                                           Little loss of bioactivity                                           Lochmann et al. 2010 \[[@B88]\]

                                                                                                                                                                                                                                                            

  PLGA/PLGA-PEG-PLGA         PVA                            100 *μ*m        HSA-BMP2\              70% initial burst (1 day)                                                           No loss of bioactivity                                               White et al. 2013 \[[@B89]\]
                                                                            60%                                                                                                                                                                             

                                                                                                                                                                                                                                                            

  PLGA                       PVA                            100--1000 nm    *Α*-1-antitrypsin\     30% initial burst (1 day)\                                                          Biological activity was preserved using BSA and *β*-cyclodextrine.   Pirooznia et al. 2012 \[[@B105]\]
                                                                            90%                    50% after 24 days                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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